Piper Jaffray Companies Brokers Lift Earnings Estimates for DexCom, Inc. (DXCM)

DexCom, Inc. (NASDAQ:DXCM) – Research analysts at Piper Jaffray Companies boosted their FY2018 earnings per share (EPS) estimates for DexCom in a report issued on Tuesday, November 6th. Piper Jaffray Companies analyst J. Mckim now anticipates that the medical device company will post earnings per share of ($0.16) for the year, up from their previous estimate of ($0.51). Piper Jaffray Companies has a “Overweight” rating and a $157.00 price objective on the stock. Piper Jaffray Companies also issued estimates for DexCom’s Q2 2019 earnings at $0.10 EPS, Q3 2019 earnings at $0.18 EPS and FY2019 earnings at $0.13 EPS.

DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, November 6th. The medical device company reported $0.17 EPS for the quarter, beating the consensus estimate of ($0.12) by $0.29. The company had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. DexCom had a net margin of 4.72% and a negative return on equity of 3.08%. The firm’s revenue was up 44.5% compared to the same quarter last year.

Several other equities analysts have also recently commented on DXCM. BidaskClub upgraded shares of DexCom from a “hold” rating to a “buy” rating in a research report on Saturday. Stephens boosted their target price on shares of DexCom from $170.00 to $160.00 and gave the company an “overweight” rating in a research report on Wednesday. Canaccord Genuity boosted their target price on shares of DexCom from $105.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. Morgan Stanley boosted their target price on shares of DexCom from $70.00 to $130.00 and gave the company an “equal weight” rating in a research report on Friday, August 3rd. Finally, Oppenheimer set a $125.00 target price on shares of DexCom and gave the company a “buy” rating in a research report on Thursday, August 2nd. Seven equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $132.50.

Shares of NASDAQ:DXCM opened at $149.46 on Friday. The company has a market capitalization of $11.74 billion, a PE ratio of -257.69 and a beta of 0.60. The company has a quick ratio of 4.62, a current ratio of 4.89 and a debt-to-equity ratio of 0.69. DexCom has a 12 month low of $49.80 and a 12 month high of $152.14.

In related news, VP Patrick Michael Murphy sold 2,372 shares of the company’s stock in a transaction that occurred on Monday, September 10th. The shares were sold at an average price of $143.69, for a total transaction of $340,832.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Steven Robert Pacelli sold 3,114 shares of the company’s stock in a transaction that occurred on Tuesday, October 23rd. The stock was sold at an average price of $128.85, for a total transaction of $401,238.90. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 157,892 shares of company stock valued at $21,864,030. 1.80% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Waddell & Reed Financial Inc. increased its position in DexCom by 164.8% during the 2nd quarter. Waddell & Reed Financial Inc. now owns 569,331 shares of the medical device company’s stock worth $54,075,000 after purchasing an additional 354,331 shares in the last quarter. UBS Group AG grew its holdings in DexCom by 76.3% during the 1st quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock worth $1,181,000 after acquiring an additional 6,890 shares during the last quarter. BlackRock Inc. grew its holdings in DexCom by 5.9% during the 2nd quarter. BlackRock Inc. now owns 4,116,421 shares of the medical device company’s stock worth $390,978,000 after acquiring an additional 228,933 shares during the last quarter. Macquarie Group Ltd. grew its holdings in DexCom by 14.4% during the 2nd quarter. Macquarie Group Ltd. now owns 236,341 shares of the medical device company’s stock worth $22,448,000 after acquiring an additional 29,825 shares during the last quarter. Finally, Federated Investors Inc. PA grew its holdings in DexCom by 97.1% during the 2nd quarter. Federated Investors Inc. PA now owns 460,209 shares of the medical device company’s stock worth $43,710,000 after acquiring an additional 226,740 shares during the last quarter.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: NASDAQ

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply